keine Finanzberatung

LLY · Eli Lilly and Company

Pharma megacap behind the GLP-1 weight-loss franchise (Mounjaro, Zepbound)

Risiko 4/10 · MODERATE RISK · GLP-1 concentration · $1,149 ▼ 0.88%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $1,149
  • Market cap $1.02T
  • P/E (ttm) 38.61
  • Div yield 0.60%
  • 52-wk range $712.05 – $1292.65
  • Index rank #11 / —

Wichtigste Risiken

  • Revenue concentration in the GLP-1 franchise (Shareholders) — HIGH
  • Copycats, compounders and drug-price pressure (Shareholders) — MED
  • Next-gen obesity pipeline disappointing in trials (Shareholders) — MED
  • Debt-funded manufacturing buildout (Bondholders) — LOW

Fazit

A phenomenal growth machine at a fair-if-full price, as long as you accept that you are really buying one franchise.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.